A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Case Rep
Päätekijät: Yamaoka, Keiko, Nagashima, Shuichi, Okada, Nobukazu, Sawayama, Nagisa, Saito, Shinsuke, Takahashi, Manabu, Okada, Kenta, Endo, Kazuhiro, Koizumi, Masaru, Sasanuma, Hideki, Ebihara, Ken, Kasajima, Atsuko, Fukushima, Noriyoshi, Sata, Naohiro, Ishibashi, Shun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
Case Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8133073/
https://ncbi.nlm.nih.gov/pubmed/34026158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.4118
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia